신경병증성 통증 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

Neuropathic pain is a chronic pain condition caused by damage or dysfunction of the peripheral or central nervous system. Common indications include diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, radiculopathy, spinal cord injury-associated pain, multiple sclerosis-related pain, and other neurological disorders. Although anticonvulsants, antidepressants, topical therapies, and selected opioids remain standard treatments, many patients continue to experience inadequate pain relief or treatment-limiting adverse effects. This unmet need is encouraging the development of highly selective therapies targeting the underlying biological mechanisms responsible for chronic neuropathic pain.

Market Drivers

Rising Prevalence of Chronic Diseases

The growing global burden of diabetes, cancer, spinal disorders, and neurodegenerative diseases continues to increase the incidence of neuropathic pain, expanding the patient population requiring long-term therapeutic management.

Demand for Non-Opioid Pain Therapies

Increasing concerns regarding opioid misuse and long-term safety are accelerating the adoption and development of non-opioid therapies with improved efficacy, better tolerability, and lower abuse potential.

Advances in Pain Biology

Improved understanding of ion channels, neuroimmune signaling, inflammatory pathways, and neuronal regeneration has enabled the identification of novel therapeutic targets that support the development of first-in-class treatments.

Precision Medicine

Biomarker-guided patient selection, molecular profiling, and personalized treatment strategies are improving clinical outcomes while supporting the development of targeted therapies for distinct neuropathic pain subtypes.

Market Restraints

Variable Treatment Response

Neuropathic pain consists of multiple disease mechanisms, resulting in considerable variability in therapeutic response and making individualized treatment strategies increasingly important.

Long-Term Safety Requirements

Because neuropathic pain often requires chronic treatment, regulatory authorities continue to require extensive long-term safety and efficacy evidence before approving innovative therapies.

High Development Complexity

Clinical development remains challenging because of heterogeneous patient populations, subjective pain endpoints, placebo effects, and complex trial designs, increasing development costs and timelines.

Market and Technology Insights

The global neuropathic pain treatment market can be segmented by drug class, treatment type, indication, route of administration, end user, and geography.

By drug class, the market includes anticonvulsants, antidepressants, topical agents, opioids, cannabinoids, sodium channel modulators, calcium channel modulators, biologics, regenerative therapies, and other emerging therapeutics. Anticonvulsants and antidepressants continue to dominate current treatment, while selective sodium channel modulators and biologics represent some of the fastest-growing innovation areas.

By treatment type, the market comprises pharmacological therapies, interventional pain management, neuromodulation, regenerative medicine, and combination therapies. Pharmacological treatment remains the largest segment, while regenerative and precision medicine approaches are expected to gain momentum during the forecast period.

By indication, the market addresses diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, spinal cord injury pain, central neuropathic pain, radiculopathy, small fiber neuropathy, and other neuropathic pain disorders. Diabetic peripheral neuropathy continues to represent the largest market because of its rapidly growing global prevalence.

By end user, the market includes hospitals, specialty pain clinics, neurology clinics, ambulatory surgical centers, rehabilitation centers, and home healthcare settings. Specialty pain clinics and multidisciplinary neurology centers continue to play a central role in long-term disease management.

Market Trends

The neuropathic pain treatment landscape continues to evolve through scientific innovation.

Key trends include:

• Increasing investment in selective sodium channel inhibitors.
• Growing development of non-opioid therapies.
• Expansion of regenerative medicine and gene therapy research.
• Greater use of biomarker-guided precision medicine.
• Integration of artificial intelligence into drug discovery.
• Increased collaboration between pharmaceutical companies and biotechnology firms.
• Growing emphasis on improving patient-reported outcomes and quality of life.

Regional Insights

North America remains the largest neuropathic pain treatment market because of its advanced healthcare infrastructure, strong pharmaceutical research ecosystem, high disease awareness, and favorable reimbursement environment. The United States continues to lead innovation in neuroscience drug development.

Europe maintains a significant market share through coordinated neurological care, standardized treatment guidelines, active academic collaboration, and strong investment in neuroscience research.

Asia-Pacific is expected to experience the fastest growth owing to increasing diabetes prevalence, rapidly improving healthcare infrastructure, expanding pharmaceutical research, and greater awareness of chronic pain management. China, Japan, South Korea, Australia, and India are emerging as major contributors to future market expansion.

Latin America and the Middle East & Africa are gradually expanding access to neuropathic pain diagnosis and treatment through healthcare infrastructure improvements and increasing availability of specialized neurological care.

Competitive Landscape

The neuropathic pain treatment market includes multinational pharmaceutical companies, biotechnology firms, specialty neuroscience developers, and pain management organizations.

Organizations continue investing in selective sodium channel inhibitors, neuroimmune modulators, biologics, RNA therapeutics, regenerative medicine, and precision medicine platforms. Strategic collaborations, licensing agreements, acquisitions, and academic partnerships continue accelerating product development and commercialization while expanding treatment options for patients with chronic neuropathic pain.

Future Outlook

The future of the neuropathic pain treatment market will increasingly focus on personalized medicine, targeted non-opioid therapies, regenerative medicine, RNA therapeutics, and artificial intelligence-assisted drug discovery. Continued advances in molecular neuroscience, biomarker-guided patient selection, and precision pharmacology are expected to improve long-term clinical outcomes while accelerating commercialization of innovative therapies through 2035.

Conclusion

The Global Neuropathic Pain Treatment Market is expected to experience sustained growth through 2035, supported by rising disease prevalence, expanding scientific understanding of pain biology, and growing demand for effective non-opioid therapies. Although disease heterogeneity, complex clinical development, and long-term regulatory requirements remain important challenges, continued advances in targeted therapeutics, regenerative medicine, and precision medicine are expected to create substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global neuropathic pain treatment market.
• Detailed evaluation of treatment modalities, emerging technologies, and innovation trends.
• Analysis of competitive strategies, pipeline developments, and commercialization opportunities.
• Insights into regulatory developments, precision medicine, and future market growth.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, consultants, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, competitive benchmarking, product portfolio planning, licensing evaluation, partnership identification, commercialization strategy, investment analysis, regulatory planning, healthcare expansion, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global neuropathic pain treatment market by drug class, treatment type, indication, route of administration, end user, and geography
• Evaluation of market dynamics, competitive landscape, technological innovations, regulatory environment, and future growth opportunities
• Assessment of clinical development, strategic collaborations, precision medicine approaches, biomarker integration, and commercialization strategies
• Analysis of anticonvulsants, antidepressants, topical agents, opioids, cannabinoids, sodium channel modulators, calcium channel modulators, biologics, regenerative medicine, neuromodulation, combination therapies, and emerging neuropathic pain treatment opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope
  • 1.1.1 Objectives
  • 1.1.2 Coverage of Approved and Pipeline Therapies
  • 1.1.3 Research Methodology Overview
• 1.2 Key Findings
  • 1.2.1 Current Pipeline Snapshot
  • 1.2.2 Innovation Trends
  • 1.2.3 Clinical Development Highlights
  • 1.2.4 Regulatory Outlook
  • 1.2.5 Competitive Landscape Summary
  • 1.2.6 Commercial Outlook
  • 1.2.7 Strategic Opportunities

2. Pipeline Overview

• 2.1 Disease Background
  • 2.1.1 Definition and Classification
  • 2.1.2 Disease Burden
  • 2.1.3 Epidemiology Overview
  • 2.1.4 Current Treatment Paradigm
• 2.2 Pipeline Landscape Overview
  • 2.2.1 Total Active Pipeline Assets
  • 2.2.2 Historical Pipeline Growth
  • 2.2.3 Pipeline Maturity Assessment
  • 2.2.4 Active Sponsors
  • 2.2.5 Emerging Developers
  • 2.2.6 Academic and Collaborative Programs
• 2.3 Pipeline Distribution by Development Phase
  • 2.3.1 Preclinical Assets
  • 2.3.2 Phase I Assets
  • 2.3.3 Phase II Assets
  • 2.3.4 Phase III Assets
  • 2.3.5 Filed/Under Regulatory Review Assets
• 2.4 Historical Clinical Progression Trends
  • 2.4.1 Phase Advancement Trends
  • 2.4.2 Annual Pipeline Evolution
  • 2.4.3 Success and Discontinuation Trends

3. Disease & Unmet Need Analysis

• 3.1 Disease Biology
  • 3.1.1 Peripheral Neuropathic Pain
  • 3.1.2 Central Neuropathic Pain
  • 3.1.3 Mixed Pain Syndromes
• 3.2 Disease Mechanisms
  • 3.2.1 Peripheral Sensitization
  • 3.2.2 Central Sensitization
  • 3.2.3 Neuroimmune Interactions
  • 3.2.4 Ion Channel Dysregulation
  • 3.2.5 Neuroinflammation
• 3.3 Current Standard of Care
  • 3.3.1 First-Line Therapies
  • 3.3.2 Second-Line Therapies
  • 3.3.3 Third-Line and Rescue Therapies
  • 3.3.4 Combination Therapy Approaches
• 3.4 Unmet Clinical Needs
  • 3.4.1 Limited Long-Term Efficacy
  • 3.4.2 Treatment Resistance
  • 3.4.3 Safety and Tolerability Challenges
  • 3.4.4 Opioid-Sparing Requirements
  • 3.4.5 Personalized Treatment Needs
• 3.5 Future Therapeutic Opportunities
  • 3.5.1 Disease-Modifying Therapies
  • 3.5.2 Precision Medicine
  • 3.5.3 Biomarker-Guided Therapy
  • 3.5.4 Digital Biomarkers and Patient Monitoring

4. Mechanism & Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Sodium Channel Modulators
  • 4.1.2 Calcium Channel Modulators
  • 4.1.3 TRP Channel Modulators
  • 4.1.4 NMDA Receptor Modulators
  • 4.1.5 Cannabinoid Pathway Modulators
  • 4.1.6 Neuroimmune Targets
  • 4.1.7 Neurotrophic Factor Pathways
  • 4.1.8 Monoaminergic Mechanisms
  • 4.1.9 GABAergic Mechanisms
  • 4.1.10 Other Emerging Mechanisms
• 4.2 Innovation Assessment
  • 4.2.1 Novel Mechanisms
  • 4.2.2 Established Mechanisms
  • 4.2.3 First-in-Class Candidates
  • 4.2.4 Best-in-Class Candidates
• 4.3 Modality Landscape
  • 4.3.1 Small Molecules
  • 4.3.2 Biologics
  • 4.3.3 Cell Therapies
  • 4.3.4 Gene Therapies
  • 4.3.5 RNA-Based Therapies
  • 4.3.6 Combination Modalities
• 4.4 Mechanism-Based Competitive Mapping

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Trials
  • 5.1.2 Completed Trials
  • 5.1.3 Recruiting Trials
  • 5.1.4 Recently Initiated Studies
• 5.2 Trial Design Benchmarking
  • 5.2.1 Study Design
  • 5.2.2 Randomization Strategy
  • 5.2.3 Control Arms
  • 5.2.4 Sample Size Distribution
  • 5.2.5 Primary Endpoints
  • 5.2.6 Secondary Endpoints
  • 5.2.7 Trial Duration
  • 5.2.8 Patient Population
  • 5.2.9 Inclusion and Exclusion Criteria
• 5.3 Clinical Performance Analysis
  • 5.3.1 Recruitment Timelines
  • 5.3.2 Enrollment Challenges
  • 5.3.3 Geographic Distribution of Trials
  • 5.3.4 Trial Completion Rates
  • 5.3.5 Dropout Trends
  • 5.3.6 Protocol Amendments
  • 5.3.7 Safety Observations
• 5.4 Clinical Success Benchmarking
  • 5.4.1 Historical Success Rates
  • 5.4.2 Failure Patterns
  • 5.4.3 Major Development Risks

6. Pipeline Segmentation

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical
    • 6.1.1.1 Pipeline Asset Profiles
    • 6.1.1.2 Molecule
• 6.1. 1.3 Developer
  • 6.1.1.4 Mechanism of Action
  • 6.1.1.5 Target Indication
  • 6.1.1.6 Development Status
  • 6.1.2 Phase I
    • 6.1.2.1 Pipeline Asset Profiles
    • 6.1.2.2 Molecule
    • 6.1.2.3 Developer
    • 6.1.2.4 Mechanism of Action
    • 6.1.2.5 Clinical Trial Summary
    • 6.1.2.6 Development Milestones
  • 6.1.3 Phase II
    • 6.1.3.1 Pipeline Asset Profiles
    • 6.1.3.2 Molecule
    • 6.1.3.3 Developer
    • 6.1.3.4 Mechanism of Action
    • 6.1.3.5 Trial Design
    • 6.1.3.6 Key Clinical Endpoints
    • 6.1.3.7 Competitive Positioning
  • 6.1.4 Phase III
    • 6.1.4.1 Pipeline Asset Profiles
    • 6.1.4.2 Molecule
    • 6.1.4.3 Developer
    • 6.1.4.4 Mechanism of Action
    • 6.1.4.5 Registration Strategy
    • 6.1.4.6 Commercial Readiness
  • 6.1.5 Filed / Under Regulatory Review
    • 6.1.5.1 Regulatory Submission Overview
    • 6.1.5.2 Expected Regulatory Decisions
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Sodium Channel Modulators
  • 6.2.2 Calcium Channel Modulators
  • 6.2.3 TRP Channel Modulators
  • 6.2.4 NMDA Receptor Modulators
  • 6.2.5 Cannabinoid-Based Therapies
  • 6.2.6 Neuroimmune Modulators
  • 6.2.7 Neurotrophic Approaches
  • 6.2.8 Other Emerging Mechanisms
• 6.3 Pipeline by Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 Cell Therapies
  • 6.3.4 Gene Therapies
  • 6.3.5 RNA Therapeutics
• 6.4 Pipeline by Target Indication
  • 6.4.1 Diabetic Peripheral Neuropathy
  • 6.4.2 Postherpetic Neuralgia
  • 6.4.3 Chemotherapy-Induced Peripheral Neuropathy
  • 6.4.4 Trigeminal Neuralgia
  • 6.4.5 Small Fiber Neuropathy
  • 6.4.6 Radiculopathy
  • 6.4.7 Central Neuropathic Pain
  • 6.4.8 Other Neuropathic Pain Conditions

7. Probability of Success & Risk Analysis

• 7.1 Clinical Development Success Rates
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Approval
• 7.2 Phase Transition Probability Modeling
  • 7.2.1 Historical Benchmarks
  • 7.2.2 Asset-Level Risk Assessment
  • 7.2.3 Mechanism-Based Success Probability
  • 7.2.4 Modality-Based Success Probability
• 7.3 Pipeline Attrition Analysis
  • 7.3.1 Scientific Risk
  • 7.3.2 Clinical Risk
  • 7.3.3 Regulatory Risk
  • 7.3.4 Commercial Risk
• 7.4 Risk-Adjusted Pipeline Assessment
  • 7.4.1 Probability-Weighted Asset Valuation
  • 7.4.2 Risk-Adjusted Revenue Potential
  • 7.4.3 Portfolio Risk Ranking

8. Launch Timeline & Commercial Potential

• 8.1 Expected Approval Timeline
• 8.2 Expected Launch Sequence
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Peak Sales Potential
  • 8.3.2 Market Access Considerations
  • 8.3.3 Pricing Potential
  • 8.3.4 Reimbursement Outlook
• 8.4 Competitive Launch Dynamics
  • 8.4.1 First-to-Market Opportunities
  • 8.4.2 Competitive Entry Timing
  • 8.4.3 Market Share Scenarios
• 8.5 Commercial Risk Assessment

9. Competitive Pipeline Landscape

• 9.1 Company-Wise Pipeline Assessment
• 9.2 Pipeline Strength Ranking
• 9.3 Company Positioning
  • 9.3.1 Market Leaders
  • 9.3.2 Emerging Challengers
  • 9.3.3 Innovation Leaders
• 9.4 Asset Concentration Analysis
• 9.5 Competitive Benchmarking
  • 9.5.1 Clinical Maturity
  • 9.5.2 Mechanism Diversity
  • 9.5.3 Geographic Footprint
  • 9.5.4 Strategic Collaborations

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
• 11.3 Germany
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Key Sponsors
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Key Sponsors
• 11.5 France
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Key Sponsors
• 11.6 Italy
  • 11.6.1 Clinical Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Key Sponsors
• 11.7 Spain
  • 11.7.1 Clinical Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Key Sponsors
• 11.8 China
  • 11.8.1 Clinical Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Key Sponsors
• 11.9 Japan
  • 11.9.1 Clinical Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Key Sponsors
• 11.10 India
  • 11.10.1 Clinical Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Key Sponsors
• 11.11 South Korea
  • 11.11.1 Clinical Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Key Sponsors
• 11.12 Australia
  • 11.12.1 Clinical Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Key Sponsors
• 11.13 Brazil
  • 11.13.1 Clinical Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Key Sponsors
• 11.14 Mexico
  • 11.14.1 Clinical Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Key Sponsors
• 11.15 Saudi Arabia
  • 11.15.1 Clinical Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Key Sponsors
• 11.16 South Africa
  • 11.16.1 Clinical Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Key Sponsors

12. Deals & Investment Landscape

• 12.1 Licensing Agreements
  • 12.1.1 Global Licensing Trends
  • 12.1.2 Asset-Level Licensing Activity
• 12.2 Co-development and Strategic Collaborations
  • 12.2.1 Industry Partnerships
  • 12.2.2 Academic Collaborations
• 12.3 Mergers and Acquisitions
  • 12.3.1 Pipeline-Driven Acquisitions
  • 12.3.2 Portfolio Expansion Strategies
• 12.4 Funding Landscape
  • 12.4.1 Venture Capital Investments
  • 12.4.2 Private Equity Activity
  • 12.4.3 Public Market Financing
  • 12.4.4 Government and Non-Profit Funding
• 12.5 Strategic Investment Trends

13. Future Outlook & Strategic Insights

• 13.1 Emerging Scientific Trends
• 13.2 Future Pipeline Evolution
• 13.3 Next-Generation Therapeutic Platforms
• 13.4 Biomarker and Precision Medicine Outlook
• 13.5 AI-Enabled Drug Discovery and Clinical Development
• 13.6 Regulatory Outlook
• 13.7 Commercial Outlook Through Forecast Period
• 13.8 Strategic Recommendations for Developers
• 13.9 Key Success Factors for Future Market Leadership

14. Methodology & Data Framework

• 14.1 Data Sources
  • 14.1.1 Clinical Trial Registries
  • 14.1.2 Regulatory Agencies
  • 14.1.3 Company Pipeline Disclosures
  • 14.1.4 Scientific Literature
  • 14.1.5 Investor Communications
• 14.2 Asset Inclusion Criteria
• 14.3 Pipeline Validation Framework
• 14.4 Phase Classification Methodology
• 14.5 Mechanism Classification Methodology
• 14.6 Probability of Success Modeling Methodology
• 14.7 Commercial Forecasting Methodology
• 14.8 Limitations and Assumptions
• 14.9 Glossary and Abbreviations